natgillin/translations-raw huggingface dataset:
The company that markets Dengvaxia will provide educational material for healthcare professionals with information on the use of Dengvaxia including the need to test for previous dengue infection and how to detect early dengue disease.
Podjetje, ki trži cepivo Dengvaxia, bo zagotovilo izobraževalno gradivo za zdravstvene delavce, ki bo vsebovalo informacije o uporabi cepiva Dengvaxia, vključno z zahtevo po testiranju na prisotnost predhodne okužbe z virusom denge in napotki za odkrivanje zgodnjih znakov bolezni.
Dengvaxia must not be given to people with weakened immune systems, including people whose immune system has been weakened by HIV infection or medicines such as cancer medicines or high doses of corticosteroids.
Cepivo Dengvaxia se ne sme dati osebam z oslabljenim imunskim sistemom, vključno tistim z oslabljenim imunskim zaradi okužbe z virusom HIV ali prejemanja zdravil proti raku ali visokih odmerkov kortikosteroidov.
There is no other vaccine for dengue disease and neither is there a specific treatment.
Za bolezen denge ne obstaja nobeno drugo cepivo ali posebno zdravljenje.
What benefits of Dengvaxia have been shown in studies?
Kakšne koristi je zdravilo Dengvaxia izkazalo v študijah?
What are the risks associated with Dengvaxia?
Kakšna tveganja so povezana z zdravilom Dengvaxia?
What is Dengvaxia and what is it used for?
Kaj je zdravilo Dengvaxia in za kaj se uporablja?
The risk of severe disease is higher in people who have been infected a second time.
Tveganje za nastop hujše oblike bolezni je večje pri ljudeh, ki so se z virusom ponovno okužili.
Available data are not sufficient to confirm how well the vaccine works in individuals previously infected by dengue virus and younger than 9 years.
Razpoložljivi podatki ne zadostujejo za potrditev učinkovitosti cepiva pri posameznikih, ki so v preteklosti že bili okuženi z virusom denge in so mlajši od 9 let.
The vaccine is given as 3 doses, 6 months apart.
Daje se v treh odmerkih, med katerimi je šestmesečni razmik.
Overall, among children aged between 9 and 16 years and who had previous dengue infection, there were around 79% fewer cases of dengue disease in children vaccinated with 3 doses of Dengvaxia compared with placebo.
Na splošno je bilo med otroci, starimi od 9 do 16 let, ki so z virusom denge že bili okuženi v preteklosti, okoli 79 % manj primerov bolezni pri tistih otrocih, ki so prejeli tri odmerke cepiva Dengvaxia, v primerjavi s placebom.
Dengvaxia can only be obtained with a prescription and should be used according to official recommendations.
Predpisovanje in izdaja cepiva Dengvaxia je le na recept, uporabljati pa se mora v skladu z uradnimi priporočili.
However, among children aged between 9 and 16 years who had not had previous dengue infection, the risk of severe dengue disease if they later became infected with the virus was higher in people vaccinated compared with those given placebo (estimated at 2 additional cases per 1000 people vaccinated over 5 years).
Vendar pa je med otroci, starimi od 9 do 16 let, ki z virusom denge še niso bili okuženi, tveganje za hujšo obliko bolezni denge v primeru kasnejše okužbe večje pri cepljenih otrocih kot pa pri tistih, ki so prejeli placebo (po ocenah dva dodatna primera na 1 000 cepljenih oseb v obdobju petih let).
Therefore, the vaccine should only be given to people who have had a previous dengue infection, as confirmed by laboratory testing.
Zato se cepivo lahko daje samo osebam, ki so z virusom denge že bili okuženi v preteklosti, kar mora biti potrjeno z laboratorijskimi testi.
Dengvaxia is effective at reducing the number of cases of dengue disease in people aged between 9 and 45 years who have had the infection in the past.
Cepivo Dengvaxia je učinkovito pri zmanjševanju števila primerov bolezni denge pri ljudeh, starih od 9 do 45 let, ki so z virusom denge že bili okuženi v preteklosti.
For the full list of side effects and restrictions with Dengvaxia, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Dengvaxia glejte navodilo za uporabo.
Children were given either 3 injections of Dengvaxia or 3 injections of placebo (a dummy vaccine) with 6 months between each injection.
Otroci so v šestmesečnih razmikih prejeli bodisi tri injekcije cepiva Dengvaxia bodisi placebo (cepivo brez učinkovine).
Dengvaxia is a vaccine used to help protect against dengue disease.
Zdravilo Dengvaxia je cepivo, ki se uporablja za zaščito pred vročico denga.
Dengvaxia contains attenuated (weakened) yellow fever viruses that have been manipulated so that they contain proteins from dengue virus.
Cepivo Dengvaxia vsebuje atenuirane (oslabljene) viruse rumene mrzlice, katerim so bile dodane beljakovine virusa denge.
Dengue disease is a mosquito-borne tropical disease caused by the dengue virus leading to mild, flulike symptoms in most people.
Denga je tropska bolezen, ki jo prenašajo komarji, povzroča pa jo okužba z virusom denge, ki se pri večini ljudi izraža v obliki blagih, gripi podobnih simptomov.
However, people who have not had dengue infection in the past may have a higher risk of severe dengue disease if they become infected with the virus after vaccination with Dengvaxia.
Pri ljudeh, ki pa s tem virusom še niso bili okuženi, je tveganje za hujšo obliko bolezni denge v primeru okužbe s tem virusom po injiciranju cepiva Dengvaxia večje.
Dengvaxia must only be given to people who have had a positive test result showing a previous infection with dengue virus.
Cepivo Dengvaxia se lahko daje samo ljudem s pozitivnim testom, ki kaže, da so že bili okuženi z virusom denge v preteklosti.
The studies included both children who had and had not been infected with dengue virus in the past.
Študije so vključevale otroke z okužbo z virusom denge v preteklosti in tiste brez nje.
When a person is given the vaccine, the immune system recognises the dengue proteins in the weakened viruses as
Ko oseba prejme cepivo, njen imunski sistem prepozna beljakovine denge v oslabljenih virusih kot „tujke“ in začne proti njim tvoriti protitelesa.
Dengvaxia is only for use in people from 9 to 45 years of age who have been infected with dengue virus before and who live in areas where this infection is endemic.
Cepivo Dengvaxia se lahko uporablja samo pri ljudeh, starih od 9 do 45 let, ki so se z virusom denge že okužili v preteklosti in živijo na endemičnih območjih.
How does Dengvaxia work?
Kako zdravilo Dengvaxia deluje?
How is Dengvaxia used?
Kako se zdravilo Dengvaxia uporablja?
10 ml (10 mg/ml) 2 vials
2 viali
Pack size
1 viala
The educational leaflet shall contain the following key elements:
Izobraževalna brošura mora vsebovati naslednje ključne elemente:
The Member States shall ensure that prior to launch the MAH provides health care professionals in dialysis centres and retail pharmacies with:
Države članice morajo zagotoviti, da imetnik dovoljenja za promet z zdravilom pred lansiranjem zdravila zdravnikom v centrih za dializo in maloprodajnim lekarnam predloži naslednje:
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES
POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA, KI JIH MORAJO UPOŠTEVATI DRŽAVE ČLANICE
• The loss of efficacy or other symptoms of the development of immunogenicity should be investigated
• Treba je raziskati izgubo učinkovitosti ali druge simptome pojava imunogenosti.
• That the use of epoetin alfa products can cause immunogenicity which in rare cases may lead to Pure Red Cell Aplasia (PRCA)
• Uporaba zdravil z epoteinom alfa lahko povzroči imunogenost, ki lahko v redkih primerih povzroči čisto aplastično anemijo (Pure Red Cell Aplasia - PRCA).
• Therefore, the sc route is not recommended for patients with CKD
• Subkutana pot odmerjanja zato ni priporočena za bolnike s KLB.
• Educational leaflet • Summary of product characteristics (SPC) and Package Leaflet and Labelling
• izobraževalno brošuro; • povzetek glavnih značilnosti zdravila, navodilo za uporabo in označevanje.
• That with other epoetin products, the risk of immunogenicity in Chronic Kidney Disease (CKD) is increased with the subcutaneous (sc) route.
• Pri drugih zdravilih, ki vsebujejo epotein, je tveganje za pojav imunogenosti pri kronični ledvični bolezni (KLB) povečano pri uporabi subkutane (s. c.) poti odmerjanja.
• There is insufficient data on Epoetin alfa HEXAL to know the size of any increased immunogenicity risk with sc use
• Podatkov o zdravilu Epoetin alfa HEXAL je premalo, da bi vedeli, za koliko se poveča tveganje za pojav imunogenosti pri subkutani uporabi zdravila.
• Any suspected case of Pure Red Cell Aplasia or development of immunogenicity should be reported to the MAH
• Vse primere suma čiste aplastične anemije ali pojava imunogenosti je treba sporočiti imetniku dovoljenja za promet z zdravilom.
Never take two doses at the same time (morning or evening).
Nikoli ne vzemite dveh odmerkov hkrati (zjutraj ali zvečer).
(see sections 4.4, 4.5 and 5.1 for available data on different combinations).
(Glejte poglavja 4.4, 4.5 in 5.1 za podatke , ki so na voljo za različne kombinacije).
Your body can also make too much sugar.
Poleg tega lahko telo izdeluje preveč sladkorja.
The red blood cells most likely represent a secondary compartment of distribution.
Rdeče krvne celice najverjetneje predstavljajo sekundarni razdelek porazdelitve.
Take the medicine pack with you.
Pakiranje zdravila vzemite s seboj.
The clinical relevance of these decreases is unknown.
Klinični pomen teh zmanjšanj ni znan.
Elimination Following administration of an oral [
Izločanje Po dajanju peroralnega odmerka [
It is unknown if this medicine is harmful to the unborn child.
Ni znano, ali lahko to zdravilo nerojenemu otroku škoduje.
Multiple-dose study: data are restricted to one study.
Študija z večkratnimi odmerki: na voljo so podatki ene študije.
(95% CI)
(95-% IZ)
Effects on plasma lipids were generally neutral.
Učinki na lipide v plazmi so bili večinoma nevtralni.
Organic cation transporters (OCT)
Organski kationski prenašalci (OCT)
However, a double dose should not be taken at the same time.
Dvojnega odmerka ne sme vzeti naenkrat.
These changes are not likely to be clinically meaningful.
Ni verjetno, da bi bile te spremembe klinično pomembne.
Doses of background anti-diabetic therapy were kept stable during the first 12 weeks, after which adjustments were permitted.
Odmerki osnovnega antidiabetičnega zdravljenje so bili prvih 12 tednov stabilni, nato jih je bilo dovoljeno prilagoditi.
When this happens, sugar (glucose) builds up in the blood.
Če se to zgodi, se sladkor (glukoza) kopiči v krvi.
This leaflet was last revised in {MM/YYYY}
Navodilo je bilo nazadnje revidirano dne {MM/LLLL}.
How much to take
Koliko zdravila vzeti
Due to the limited nature of the data set the results should be interpreted cautiously.
Zaradi omejenega nabora podatkov, je pri interpretaciji rezultatov potrebna previdnost.
Your doctor will tell you exactly the dose of this medicine to take.
Zdravnik vam bo natančno povedal, kolikšen odmerek zdravila morate jemati.
Safety data from this study was in line with previous known safety profile of linagliptin.
Podatki o varnosti iz te študije so bili skladni s prej znanim varnostnim profilom linagliptina.
Tell your doctor if you are taking, have recently taken or might take any other medicines.
Obvestite zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
In patients at an increased risk of further progression of renal impairment and in the elderly, renal function should be assessed more frequently, e.g. every 3-6 months.
Pri bolnikih s povečanim tveganjem dodatnega napredovanja okvare ledvic in pri starejših je treba delovanje ledvic oceniti pogosteje, na primer vsake 3 do 6 mesecev.
The starting dose is at most half of the maximum dose.
Začetni odmerek je največ polovica največjega odmerka.
The mean volume of distribution (Vd) ranged between 63-276 l.
Povprečni volumen porazdelitve (Vd ) je med 63 in 276 l.
Concomitant use not recommended
Sočasna uporaba ni priporočljiva
However, if it is nearly time for the next dose, skip the missed dose.
Vendar, če je že skoraj čas za naslednji odmerek, pozabljenega izpustite.
If you forget to take a dose, take it as soon as you remember it.
Če ste pozabili vzeti odmerek, ga vzemite takoj, ko se spomnite.
In that case, the missed dose should be skipped.
V tem primeru mora pozabljeni odmerek izpustiti.
Children and adolescents This medicine is not recommended for use in children and adolescents under 18 years.
To zdravilo ni priporočeno za zdravljenje otrok in mladostnikov, mlajših od 18 let.
There is no experience with doses above 600 mg in humans.
Z odmerki nad 600 mg pri ljudeh ni izkušenj.
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), or very rare (< 1/10,000) and not known (cannot be estimated from the available data).
Po pogostnosti so opredeljeni kot zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000) ali zelo redki (< 1/10.000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Other side effects of Jentadueto include:
Drugi neželeni učinki zdravila Jentadueto vključujejo:
Oral contraceptives:
Peroralni kontraceptivi:
HbA1c (%) Number of patients n = 65 n = 135
HbA1c (%) Število bolnikov n = 65 n = 135
A GFR should be assessed before initiation of treatment with metformin containing products and at least annually thereafter.
GFR je treba oceniti pred uvedbo zdravljenja z zdravili, ki vsebujejo metformin, nato pa vsaj enkrat letno.
Further symptoms are reduced body temperature and heartbeat.
Dodatna simptoma sta znižana telesna temperatura in zmanjšan srčni utrip.
If no adequate strength of Jentadueto is available, individual monocomponents should be used instead of the fixed dose combination.
Če ni na voljo ustrezna jakost zdravila Jentadueto, je treba namesto fiksne kombinacije uporabiti posamične monokomponente.
Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 hours.
Po peroralnem odmerku je navidezni končni razpolovni čas izločanja približno 6,5 ure.
What is type 2 diabetes?
Kaj je sladkorna bolezen tipa 2
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 20 July 2012
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 20. julij 2012 Datum zadnjega podaljšanja: 22. marec 2017
The absolute bioavailability of linagliptin is approximately 30%.
Absolutna biološka uporabnost linagliptina je približno 30-odstotna.
This can lead to serious medical problems like heart disease, kidney disease, blindness, and amputation.
Posledica so lahko resne zdravstvene težave, kot so srčna bolezen, ledvična bolezen, slepota in amputacija.
Plasma protein binding is negligible.
Vezava na beljakovine v plazmi je zanemarljiva.
Patients should be informed of the characteristic symptoms of acute pancreatitis.
Bolnike je treba poučiti o značilnih simptomih akutnega pankreatitisa.
* PY=patient years ** Test on non-inferiority to demonstrate that the upper bound of the 95% CI for the hazard ratio is less than 1.3
* BL = bolnik-let ** preskus neinferiornosti, ki pokaže, da je zgornja meja 95-% IZ za razmerje tveganja nižja od 1,3
The mean age for study population was 64 years and included 2030 (34%) patients ≥ 70 years of age.
Povprečna starost študijske populacije je bila 64 let, vključevala pa je 2030 (34 %) bolnikov, starih ≥ 70 let.
The adverse reactions are listed by system organ class and absolute frequency.
Neželeni učinki so navedeni po organskih sistemih in absolutni pogostnosti.
Type 2 diabetes is a condition in which your body does not make enough insulin, and the insulin that your body produces does not work as well as it should.
Sladkorna bolezen tipa 2 je bolezensko stanje, pri katerem telo ne izdeluje dovolj insulina, tisti, kolikor ga telo izdeluje, pa ne deluje tako, kot bi moral.
When starting or using such products in combination with metformin, close monitoring of renal function is necessary.
Ob uvedbi ali uporabi teh zdravil v kombinaciji z metforminom je potrebno skrbno spremljanje delovanja ledvic.
Metformin is a substrate of both transporters OCT1 and OCT2.
Metformin je substrat za prenašalca OCT1 in OCT2.
• Any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis)
• vse vrste akutne metabolične acidoze (kot sta laktacidoza, diabetična ketoacidoza)
Stop taking this medicine immediately and contact a doctor or the nearest hospital straight away (see section 2).
Takoj prenehajte jemati to zdravilo in se nemudoma posvetujte z zdravnikom ali takoj pojdite v najbližjo bolnišnico (glejte poglavje 2).
If necessary, the dose of the anti-hyperglycaemic medicinal product should be adjusted during therapy with the other medicinal product and on its discontinuation.
Če je potrebno, je treba odmerek antihiperglikemičnega zdravila prilagoditi med zdravljenjem z drugim zdravilom in ob njegovi ukinitvi.
Diabetic skin problems are a common complication of diabetes.
Diabetične težave s kožo so pogost zaplet sladkorne bolezni.
Component of a multipack, cannot be sold separately.
Del večkratnega pakiranja, ki ni za posamično prodajo.
If any of the above apply to you, talk to your doctor for further instructions.
Če kar koli od zgoraj navedenega velja za vas, se za več navodil posvetujte z zdravnikom.
If acidosis of either form occurs, Jentadueto must be stopped immediately and other appropriate corrective measures initiated.
Če se pojavi katerakoli acidoza, je treba zdravilo Jentadueto nemudoma ukiniti in uvesti druge ustrezne korektivne ukrepe.
• Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
• preobčutljivost na učinkovini ali katero koli pomožno snov, navedeno v poglavju 6.1
Metformin must be discontinued at the time of surgery under general, spinal or epidural anesthesia.
Uporabo metformina je treba v času kirurškega posega pod splošno, spinalno ali epiduralno anestezijo prekiniti.
What Jentadueto is and what it is used for
Kaj je zdravilo Jentadueto in za kaj ga uporabljamo
Ketoacidosis is a condition in which substances called ‘ketone bodies' accumulate in the blood and which can lead to diabetic pre-coma.
Ketoacidoza je stanje, pri katerem se snovi, imenovane 'ketonska telesa', kopičijo v krvi, kar lahko povzroči diabetično predkomo.
The safety and efficacy of Jentadueto in children and adolescents aged 0 to 18 years have not been established.
Varnost in učinkovitost zdravila Jentadueto pri otrocih in mladostnikih od rojstva do 18 let nista dokazani.
Your doctor may ask you to stop Jentadueto.
Vaš zdravnik vam bo morda naročil, da zdravilo Jentadueto prenehate jemati.
If you have symptoms of acute pancreatitis, like persistent, severe abdominal pain, you should consult your doctor.
Če imate simptome akutnega pankreatitisa, kot je persistentna, huda bolečina v trebuhu, se posvetujte s svojim zdravnikom.
The observed pharmacokinetic and pharmacodynamic responses were consistent with those found in adult subjects.
Opaženi farmakokinetični in farmakodinamični odzivi so bili skladni s tistimi, ki so jih opazili pri odraslih preiskovancih.
The name of your tablet is Jentadueto.
Vaša tableta se imenuje zdravilo Jentadueto.
• Severe renal failure (GFR <30 ml/min).
• huda ledvična odpoved ( GFR < 30 ml/min)
Use of DPP-4 inhibitors has been associated with a risk of developing acute pancreatitis.
Uporaba zaviralcev DPP-4 je povezana s tveganjem za nastanek akutnega pankreatitisa.
The use of linagliptin has not been studied in pregnant women.
Uporabe linagliptina pri nosečnicah niso proučevali.
If needed, dose adjustment of metformin may be considered as OCT inhibitors/inducers may alter the efficacy of metformin.
Če je potrebno, odmerek metformina lahko prilagodimo, saj lahko zaviralci/induktorji OCT spremenijo učinkovitost metformina.
Sulphonylureas and insulin are known to cause hypoglycaemia.
Za sulfonilsečnine in insulin je znano, da povzročajo hipoglikemijo.
The European Medicines Agency has waived the obligation to submit the results of the studies with Jentadueto in all subsets of the paediatric population in type 2 diabetes (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Jentadueto za vse podskupine pediatrične populacije pri sladkorni bolezni tipa 2 (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Both incretin hormones are involved in the physiological regulation of glucose homeostasis.
Oba inkretinska hormona sodelujeta pri fiziološkem uravnavanju homeostaze glukoze.
Keep taking Jentadueto until your doctor tells you to stop.
Zdravilo Jentadueto jemljite, dokler vam vaš zdravnik ne naroči, da ga prenehate jemati.
• Hepatic impairment, acute alcohol intoxication, alcoholism (see section 4.5).
• jetrna okvara, akutna zastrupitev z alkoholom, alkoholizem (glejte poglavje 4.5)
Remember to take all medicines as directed by your doctor to achieve the best results for your health.
Vsa zdravila jemljite tako, kot vam bo naročil vaš zdravnik, da bo njihov učinek na vaše zdravje najboljši.
For prevention, it is recommended that Jentadueto be taken during or after meals.
Da bi jih preprečili, je priporočeno jemanje zdravila Jentadueto med jedjo ali po njej.
The amount of Jentadueto that you will take varies depending on your condition and the doses you currently take of metformin and/or individual tablets of linagliptin and metformin.
Količina zdravila Jentadueto, ki jo boste jemali, bo lahko različna, kar je odvisno od vašega stanja in odmerkov metformina in/ali posameznih tablet linagliptina in metformina, ki jih trenutno jemljete.
In the event of an overdose, it is reasonable to employ the usual supportive measures, e.g. remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute clinical measures if required.
Po zaužitju prevelikega odmerka je smiselno uvesti običajne podporne ukrepe, na primer odstraniti neabsorbirano vsebino iz prebavil, uvesti klinično spremljanje in po potrebi izvesti klinične ukrepe.
Patients and/or care-givers should be informed of the risk of lactic acidosis.
Bolnike in/ali negovalce je treba opozoriti na tveganje laktacidoze.
Analysis of the results for overweight patients treated with metformin after failure of diet alone showed:
Analiza izsledkov pri bolnikih s preveliko telesno maso, ki so se zdravili z metforminom po neuspešni dieti, je pokazala:
GFR should be assessed before treatment initiation and regularly thereafter, see section 4.2.
GFR je treba oceniti pred uvedbo zdravljenja, nato pa v rednih presledkih, glejte poglavje 4.2.
This is to help keep your blood sugar under control.
Tako bo vaš krvni sladkor urejen.
Along with diet and exercise, this medicine helps to improve the levels and effects of insulin after a meal and lowers the amount of sugar made by your body.
Ob dieti in telesni aktivnosti to zdravilo izboljša raven in učinek insulina po jedi in zmanjša količino sladkorja, ki nastaja v telesu.
The blood peak is lower than the plasma peak and appears at approximately the same time.
Največja koncentracija v krvi je manjša od največje koncentracije v plazmi in se pojavi ob približno istem času.
In patients with stable chronic heart failure, Jentadueto may be used with a regular monitoring of cardiac and renal function.
Pri bolnikih s stabilnim kroničnim srčnim popuščanjem se zdravilo Jentadueto lahko uporablja ob rednem spremljanju delovanja srca in ledvic.
The following statements reflect the pharmacokinetic properties of the individual active substances of Jentadueto.
Trditve v nadaljevanju temeljijo na farmakokinetičnih lastnostih posamičnih zdravilnih učinkovin v zdravilu Jentadueto.
Both treatments were added to standard of care targeting regional standards for HbA1c and CV risk factors.
Obe terapiji sta bili dodani standardni terapiji na podlagi regionalnih standardov za vrednosti HbA1c in tveganja za srčno-žilna obolenja.